Molecular Staging Overview

  • Year Founded
  • 1998

Year Founded

  • Status
  • Acquired/​Merged

  • Latest Deal Type
  • M&A

  • Latest Deal Amount
  • $35.2M

Molecular Staging General Information

Description

Developer of technologies for the detection and measurement of proteins and nucleic acids. The company provides technologies for proteomics, genomics, pharmacogenomics and diagnostics applications. The company develops Whole Genome Amplification (WGA) technology which is designed to eliminate limitations created by scarce quantities of DNA samples.

Contact Information

Ownership Status
Acquired/Merged
Financing Status
Formerly VC-backed
Corporate Office
  • 300 George Street
  • New Haven, CT 06511
  • United States
+1 (203)
Primary Industry
Biotechnology
Other Industries
Drug Discovery
Discovery Tools (Healthcare)
Acquirer
Vertical(s)
Corporate Office
  • 300 George Street
  • New Haven, CT 06511
  • United States
+1 (203)

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Molecular Staging Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
6. Merger/Acquisition 27-Sep-2004 $35.2M Completed Generating Revenue
5. Grant 08-Oct-2001 Completed
4. Later Stage VC (Series D) Completed Generating Revenue
3. Later Stage VC (Series C) 06-Nov-2000 Completed Generating Revenue
2. Early Stage VC (Series B) 04-Feb-1999 $5.17M $18.7M Completed Product Development
1. Early Stage VC (Series A) 01-Jan-1998 $13.5M $13.5M Completed Product Development
To view Molecular Staging’s complete valuation and funding history, request access »

Molecular Staging Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate ($) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Series D
Series C2
Series C1
Series B 700,000 $0.010000 $7.38 $7.38 1x $7.38 3.4%
Series A 4,500,000 $0.010000 $0.24 $3 $3 1x $3 21.87%
To view Molecular Staging’s complete cap table history, request access »

Molecular Staging Patents

Molecular Staging Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
EP-1585833-A2 Rolling circle amplification of rna Active 31-Dec-2002
EP-1585833-A4 Rolling circle amplification of rna Active 31-Dec-2002
AU-2003293023-A8 Chemokine parc suppresses specific cytokine production Inactive 26-Nov-2002
AU-2003293023-A1 Chemokine parc suppresses specific cytokine production Inactive 26-Nov-2002
US-20040101510-A1 Anticancer agents; antiarthritic agents; antiproliferative agents; measurement protein, calibration cell proliferation Inactive 26-Nov-2002 A61K38/195
To view Molecular Staging’s complete patent history, request access »

Molecular Staging Former Investors (8)

Investor Name Investor Type Holding Investor Since Participating Rounds
CHL Medical Partners Venture Capital Minority
CIBC Capital Partners Investment Bank Minority
Cooper Hill Partners Hedge Fund Minority
Domain Associates Venture Capital Minority
Investor PE/Buyout Minority
You’re viewing 5 of 8 investors. Get the full list »

Molecular Staging FAQs

  • When was Molecular Staging founded?

    Molecular Staging was founded in 1998.

  • Where is Molecular Staging headquartered?

    Molecular Staging is headquartered in New Haven, CT.

  • What industry is Molecular Staging in?

    Molecular Staging’s primary industry is Biotechnology.

  • Is Molecular Staging a private or public company?

    Molecular Staging is a Private company.

  • What is the current valuation of Molecular Staging?

    The current valuation of Molecular Staging is .

  • What is Molecular Staging’s current revenue?

    The current revenue for Molecular Staging is .

  • How much funding has Molecular Staging raised over time?

    Molecular Staging has raised $73.9M.

  • Who are Molecular Staging’s investors?

    CHL Medical Partners, CIBC Capital Partners, Cooper Hill Partners, Domain Associates, and Investor are 5 of 8 investors who have invested in Molecular Staging.

  • When was Molecular Staging acquired?

    Molecular Staging was acquired on 27-Sep-2004.

  • Who acquired Molecular Staging?

    Molecular Staging was acquired by Qiagen.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read blog »
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process »